Cell Biotech Co., Ltd. (KOSDAQ: 049960)

Market Cap	91.71B
Revenue (ttm)	54.10B
Net Income (ttm)	12.97B
Shares Out	6.84M
EPS (ttm)	1,893.42
PE Ratio	7.08
Forward PE	n/a
Dividend	450.00 (3.34%)
Ex-Dividend Date	n/a

Volume	9,467
Open	13,470
Previous Close	13,480
Day's Range	13,270 - 13,470
52-Week Range	10,500 - 16,950
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Cell Biotech

Cell Biotech Co., Ltd., a biotechnology company, develops lactic acid bacteria products in South Korea and internationally. It engages in the probiotics, microbiome, and anticancer new drug businesses. The company sells its products through partnerships with multinational companies and local retailers under the DUOLAC, DUOLAB, LACTOClear, and LAB2PRO brand names. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 114
• Stock Exchange: KOSDAQ
• Ticker Symbol: 049960

Financial Performance

In 2023, Cell Biotech's revenue was 53.79 billion, an increase of 6.46% compared to the previous year's 50.53 billion. Earnings were 6.30 billion, a decrease of -23.87%.